SH-110, a liquid most cancers remedy for glioma, earned orphan drug standing from the FDA, serving to sufferers who wrestle to swallow drugs entry remedy.
The U.S. Meals and Drug Administration (FDA) granted orphan drug designation to SH-110, a liquid treatment designed to deal with glioma, a uncommon type of mind most cancers, in sufferers who’ve hassle swallowing drugs.
“For too lengthy, many sufferers with glioma and their pharmacists and caregivers had no different alternative however to interrupt open capsules and expose themselves to pointless hazards,” Sharon Cunningham, CEO of Shorla, mentioned within the information launch. “SH-110 is a proprietary product that gives them a safer and extra handy formulation to deal with this uncommon mind most cancers.”
SH-110 is anticipated to enhance remedy flexibility and entry for sufferers with glioma, which impacts about 13,000 adults and a couple of,000 kids within the U.S. yearly, in keeping with the Nationwide Mind Tumor Society.
Whereas SH-110 presents broader dosing and administration choices to assist compliance and protection, its most important profit could also be for sufferers who’ve issue swallowing, often known as dysphagia, as per the discharge.
These people usually rely on specialised compounding pharmacies or should modify their very own capsules to take their treatment. SH-110 will probably be a part of an increasing catalog of patient-friendly most cancers therapies developed by Shorla and lately accredited by regulators, in keeping with Shorla.
“It is a difference-maker within the lives of those that undergo from glioma,” Orlaith Ryan, chief technical officer and co-founder of Shorla, mentioned within the information launch. “SH-110 enhances our different Shorla therapies which are designed to be simpler for sufferers to make use of and for caregivers and suppliers to manage.”
SH-110 marks the third oral liquid in Shorla’s portfolio of accessible most cancers therapies and displays the corporate’s continued concentrate on creating therapies that enhance each security and usefulness.
Orphan drug designation is standing granted by the FDA to medicine supposed to deal with uncommon illnesses or circumstances that have an effect on fewer than 200,000 individuals in the US, in keeping with the FDA. It offers incentives comparable to tax credit, consumer price waivers, and 7 years of market exclusivity upon approval.
Extra Liquid Suspension Remedy FDA Approvals
Alongside SH-110, Shorla presents two different liquid suspension therapies: Jylamvo, an oral methotrexate for acute lymphoblastic leukemia (ALL) and different cancers, and Imkeldi, a liquid model of imatinib utilized in ALL, persistent myeloid leukemia, gastrointestinal stromal tumors and extra indications.
Jylamvo was initially accredited by the FDA in November 2022 for choose makes use of in adults with ALL, cutaneous T-cell lymphoma, and relapsed or refractory non-Hodgkin lymphoma. The approval was expanded in October 2024 to assist remedy of kids with ALL as effectively.
Jylamvo is an orange-flavored liquid type of methotrexate designed to take away the necessity for tablet splitting, crushing, or compounding right into a liquid. In accordance with the Nationwide Most cancers Institute, methotrexate may match by blocking cells from utilizing folic acid to make DNA, which might help destroy most cancers cells and scale back immune exercise.
Jylamvo additionally is available in a formulation that is still secure at room temperature for 90 days, so it doesn’t require chilly chain storage earlier than dishing out.
“This approval follows Jylamvo’s profitable use in grownup sufferers and represents a crucial step ahead in addressing the unmet want of pediatric care in oncology and autoimmune illnesses,” Cunningham mentioned in a earlier information launch from Shorla Oncology. “We’re happy to supply a handy, patient-friendly various for each grownup and pediatric sufferers within the U.S., as we proceed to develop modern options for these with restricted remedy choices.”
Imkeldi gained FDA approval in November 2024.
Reference:
- “Shorla Oncology declares FDA orphan drug designation for SH-110 to deal with uncommon mind most cancers utilizing oral liquid,” Shorla Oncology. Accessed July 16, 2025.
- “Shorla Oncology declares US Meals and Drug Administration expanded approval of JYLAMVO (methotrexate), an oncology and autoimmune drug for pediatric indications,” by Shorla Oncology. Accessed July 16, 2025.
- “Shorla Oncology declares FDA approval of Imkeldi (imatinib) oral resolution, an oral liquid for remedy of sure leukemias and different cancers,” by Shorla Oncology. Accessed July 16, 2025.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
